Member Info for 1DayRodney

I would say today's RNS was positive. Asset and strategy wise, we are leaps and bounds ahead of our situation this time last year!

Going on information harvested from RNS's and recent interviews, there is going to be further extensive explorations into the current two gold claims. I would say this is another year away before the price makes any significant gains.

IMHO I would be looking for an SP of 5/6p by the end of 2027 if the speculations made in today's RNS come to fruition.

Like I said before, there's too many fidgety 'get rich quick' traders at this price to gain any real momentum, at least until PEAs or JVs are announced.

I caveat that further with a statement made in today's RNS

'The Company also continues to evaluate additional project opportunities in line with its stated investment criteria, and the Board remains open to value-accretive additions to the portfolio where the right asset presents itself.'

This could affect either way the SP depending on how any new 'projects' are acquired, if there's any further dilution and, of course, the acquisitions' credentials...

Interesting times ahead if you're not a nervous investor and are happy to sit on your paper egg 😀

I believe the 'around' June FDA submission is for the CYP2C19 assay, not the MT-RNR1.

'FDA 510(k) submission for Genedrive® CYP2C19 currently anticipated around June 2026, pending completion of studies, with an expected 3-4 month review period' RNS 31-12-25.

The date of submission for the MT-RNR1 test is yet to be confirmed.

'In the US, FDA submission under the de novo Breakthrough Designation route is being planned.'

RNS 31-12-25.

.... Hello Mr/Mrs/Miss/Ms/They New Chairperson?

Dr Ian Gilham should be on his way in a few days as far as I understand....

'he anticipates stepping down as Chairman and a Director of genedrive by the end of June 2026' (RNS 16-05)

Wonder how the hunt for the next Chairperson is progressing...

🤞we can rapidly move on from the commercial stagnation we currently find ourselves in!

See, us LTHs do have a sense of humour - bl@@dy well need it here 😅

"£1 would do nicely! 😂"

This time next year...

Liquidity will be be low until major news lands.

Two shareholders alone hold over 30% of the shares and the majority of the rest are probably held by brokers on behalf of sticky handed long-term PIs.

Interesting interview. Thank you for highlighting it.

The overall Molly plot including the 'boomerang' area seems to be the key Jangada asset now.

The speakers also highlighted there was to be a far more detailed survey of the whole Molly claim over this year and maybe part of next, which Paolo was also quick to highlight was "fully funded".

It was good that they talked about a realistic timescale for a full Molly PEA (by the end of '27). There was also an as yet unproven, optimistic but reasoned valuation of 0.5 - 1M oz just from the gold for the overall site (plus the other commodity metals).

With current price levels, overall I personally think it makes Jangada an interesting medium to longer term investment 'gamble'. But then again, isn't every investment a gamble? Remember, the BOD are significant % holders here.

The price will still probably be a bit 'choppy' especially due short term profit seeking players at this low price, but I believe there is potential for serious multiples here if the results and surveys prove the initial evaluations of all sites.

This BBoard seems full of news hungry, nervous desperados, but unfortunately the company is at the mercy of external labs at this stage of exploration. No doubt every man and his dog has been sending in samples with the recent gold price levels!

There'll probably be further raises/dilution to bring these assets to production, but hopefully these will be kept to a minimum with partnerships or smelting agreements etc. Or, of course, we could be subject to a takeover/merger!

Toe in or toe out? It's really up to you!

all IMHO...

What a numpty thing to post.

How 'bout you tell us your research for such a bold and definitive statement?

Next you'll be saying 'nudge, nudge, wink, wink...say no more..' 🙄

@EmCarrot

'For the 14 Hospital trial, then we wait for the NICE rollout decision early July.'

Is that decision not until 2027?

"Funding for PALOH-UK sites is provided by the Office for Life Sciences ("OLS") and National Institute for Health and Care Research ("NIHR") and will cease by June 2026, with some sites completing earlier. Subsequent review and issuance of final guidance by NICE is expected around July 2027."

Which is an absolutely ridiculous timescale - so much for NICE 'fastrack' 🤨

However, Gino stated in the same RNS (referring to Sussex hospital continued uptake).

"We are in active discussions with other hospitals in the PALOH-UK programme to support the transition of our MT-RNR1 test from PALOH-UK based funding to embedding into routine practice to ensure that newborn babies across the UK continue to have access to this preventive test."

So hopefully we're going to get at least some continuance of business from those other hospitals already in the study.

The problem we don't know what the current figures are!

• Assets (including IP and patents) - 🤷‍♂️

• Turnover - £? will find out in Dec

• Potential - 🔮... somewhere between 'sky's the limit' and 🪦. Unfortunately the 'potential' is also very much in the hands of NICE and FDA.

At the moment, I think the price and it's controlled growth are about right. For me personally, I would like to think that I could make acceptable profit here one day and for the Genedrive product to continue to thrive in one form or another.

@Amers

You've been bandying the '10p within 12mths' figure around for a while now.

What's your reasoning/evidence for this or are you really Septic Peg?

https://youtu.be/s6kCSsfp_Tk?si=dVZgh469GUHgD9KZ

🔮

Fingers crossed the new non-exec chair and directors search is a swift and fruitful one.

Hopefully one will be sales orientated. We really need a fresh and concentrated drive towards substantial revenue and make a profit.

We should aim to be rapidly moving towards a point where any future raise are small and for product/assay expansion, not just to keep the lights on💡!

Despite certain posters' obvious shenanigans and ramping here, I believe the SP here will climb slowly but steadily with the odd boost on sales or qualification news.

~~~~~~~~

After all, I myself am looking forward to top-slicing when we hit 15p this time next year, while continuing to hold the balance for the 30p buyout shortly after (💭😉).

My source..

https://www.dictionary.com/browse/ironic

Didn't think Gino was going anywhere and was still CEO with Russ still CFO...

"I am excited to be joining the Board and working with Gino and Russ as the Company drives adoption and executes its commercial strategy in the UK and internationally."

or have I misunderstood your comment BigH ?🤔

Fingers crossed we can make firm progress towards production and maybe get some capital flowing in with the existing assets before we get diluted further with another site purchase.

In my mind, we've got to to prove Molly & Para are profitable to increase confidence all round, demonstrating that the company's research and purchase process can be trusted and that the company is investable.

GLA

Great watching this creep up to the 800 milestone.

It'll be interesting to see if it climbs much higher above the mark, and maintain it, as we creep towards the end of year merger with its associated capital cost and 18% share dilution.

Seems the market believes it's the right move...

Nissangtr786 wrote "That could mean 3p could be very close with news due next month."

You won't be here then anyways nissan - thought you were selling when it reached 2.3p! 😆

Lionel said

"The test NUH (Nottingham) is using is Genomadix CUBE. I’m curious why they chose Genomadix over Genedrive, it seems like a strange decision, that’s why we have not seen any RNS or press release from Genedrive ."

In my deep, dark memory, I believe there was a previously posted link of Teams YouTube video in which there was a discussion between several hospital depts/users about this POC test. One of the attendees said that Genomadix offered a free/subsidised trial for their product but Genedrive didn't offer the same, so the hospital had gone with them instead.

Don't quote me on it, and things may have changed, but that could be a reason.

Need the get this bl@@dy red tape torture out of the way! There must be so many innovative companies out there with diamond products, but they just hit the test/procurement wall and fade away due to running out money - absolutely criminal.

GLA

"Even 2.3p I would take now"

God dammit! Stop ya whining a make like you've got a pair!

Your many, many, many, many, many "I'd sell for xx" prices over the many, many months have been and gone many, many, (you get the idea..) times.

JUST SELL UP NOW and invest in Space X or something!!

😉

BOD still 'Bullish' - todays X post

"Rising bond yields are pressuring gold prices in the short term but we believe this is likely a cyclical phase, not a structural shift. Inflation risks, geopolitical uncertainty, and central bank buying still provide strong long-term support for gold. We remain bullish about our gold strategy and as reported in last announcement, await full results from Molly Gold Project drilling programme. #gold #mining #goldequities"

🤞the Molly results are 🎇 and not 💩 - would be nice to stop the creeping price drop and move up a step or two!